The company
Teva Pharmaceutical Industries Limited
TEVA · NYSE
Health CarePharmaceuticalsLeading
TEVA stood above a rising 150-day average in 49 of the last 52 weekly readings, including each of the last 13 weeks. It is 15.3% above that average now. Pharmaceuticals: 35% of its 74 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 13 in a row
- Industry in uptrend
- 35% -4 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $206.5M
- Officials’ trades on record
- 25
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 49 of 52 weeks.
23 Apr – 22 Oct
Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
25 disclosed lines: House 22, Senate 3, executive 0; 11 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Alan Armstrong Senate: U.S. Senate eFDSenator | bought | $1k–$15k | 30 Mar 2026filed 21 Jul 2026 |
| Greg Gianforte House: U.S. House ClerkMT00 | bought | $15k–$50k | 13 Nov 2020filed 2 Dec 2020 |
| Donna E. Shalala House: U.S. House ClerkFL27 | sold | $1k–$15k | 7 May 2020filed 15 May 2020 |
| David E. Price House: U.S. House ClerkNC04 | sold | $1k–$15k | 19 Jun 2019filed 11 Jul 2019 |
| Patty Murray Senate: U.S. Senate eFDSenator | soldspouse | $1k–$15k | 15 Jun 2017filed 22 Jun 2017 |
| Cheri Bustos House: U.S. House ClerkIL17 | sold | $1k–$15k | 30 Jan 2017filed 9 Feb 2017 |
| James B. Renacci House: U.S. House ClerkOH16 | sold | $15k–$50k | 20 Dec 2016filed 5 Jan 2017 |
| Angus S. King, Jr. Senate: U.S. Senate eFDSenator | soldspouse | $1k–$15k | 19 Oct 2016filed 10 Nov 2016 |
| K. Michael Conaway House: U.S. House ClerkTX11 | sold | $1k–$15k | 12 Sep 2016filed 12 Oct 2016 |
| K. Michael Conaway House: U.S. House ClerkTX11 | sold | $1k–$15k | 11 May 2016filed 3 Jun 2016 |
| K. Michael Conaway House: U.S. House ClerkTX11 | sold | $1k–$15k | 4 May 2016filed 3 Jun 2016 |
| James B. Renacci House: U.S. House ClerkOH16 | bought | $1k–$15k | 12 Feb 2016filed 25 Feb 2016 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months46
Buyers · sellers0 · 14
| Who | Did | Shares | Traded |
|---|---|---|---|
| Roberto MignoneDirector | sold | 367,600at $39.06 | 18 Sep 2026filed 22 Sep 2026 |
| Brian SavageInterim Chief Legal Officer | sold | 4,503at $38.69 | 18 Sep 2026filed 22 Sep 2026 |
| Brian SavageInterim Chief Legal Officer | sold | 2,525at $39.15 | 18 Sep 2026filed 22 Sep 2026 |
| Brian SavageInterim Chief Legal Officer | sold | 314at $38.70 | 18 Sep 2026filed 22 Sep 2026 |
| Ronit Satchi-FainaroDirector | sold | 415at $37.25 | 21 Aug 2026filed 25 Aug 2026 |
| Amir WeissChief Accounting Officer | sold | 6,945at $37.61 | 21 Aug 2026filed 25 Aug 2026 |
| Amir WeissChief Accounting Officer | sold | 2,500at $37.63 | 21 Aug 2026filed 25 Aug 2026 |
| Evan LippmanEVP, Business Development | sold | 18,600at $36.57 | 17 Aug 2026filed 19 Aug 2026 |
| Tal Zvi ZaksDirector | sold | 17at $34.87 | 5 Aug 2026filed 10 Aug 2026 |
| Eric A. HughesSee "Remarks" | sold | 25,578at $34.88 | 3 Aug 2026filed 5 Aug 2026 |
| Placid JoverSee "Remarks" | sold | 12,827at $34.88 | 3 Aug 2026filed 5 Aug 2026 |
| Matthew ShieldsEVP, Global Operations | sold | 9,989at $32.19 | 18 Jun 2026filed 22 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Teva Pharmaceutical Industries Ltd: UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Diseasefinanznachrichten.de · 20 Oct 2026Teva Pharmaceutical Industries Ltd: Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndromefinanznachrichten.de · 2 Oct 2026Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries' (TEVA) Margin Expansioninsidermonkey.com · 1 Oct 2026Teva Pharmaceutical Industries Ltd: Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA (denosumab-adet), a Biosimilar to Xgeva (denosumab)finanznachrichten.de · 28 Sep 2026Teva Pharmaceutical Industries Ltd: New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patientsfinanznachrichten.de · 18 Sep 2026Teva Pharmaceutical Industries Ltd: Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Carefinanznachrichten.de · 16 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.